Genomic profiling of cancer of unknown primary site

Genomic profiling of cancer of an unknown primary site (CUP) found at least one clinically relevant genomic alteration in most of the samples tested, an indication of potential to influence and personalise therapy for this type of cancer, which responds poorly to classical chemotherapy, according to a study published online on February 12 by JAMA Oncology. Read more here.